Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 53

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 53
---
6,893,000 
  
    Income (loss) from operations 

    $14,924,000  

    $(4,077,000)

Substantially
all revenue is attributable to the U.S. All long-lived assets at September 30, 2025 and December 31, 2024 were located in the U.S.

    29

Revenues
by segment are further described as follows:

SCHEDULE
OF REVENUES BY SEGMENT

    For the Three Months Ended  
    For the Nine Months Ended 

    September 30,  
    September 30, 

    2025  
    2024  
    2025  
    2024 
  
    IHEEZO 
    $21,907,000  
    $12,882,000  
    $45,465,000  
    $26,498,000 
  
    VEVYE 
     22,626,000  
     5,186,000  
     62,783,000  
     12,099,000 
  
    Other branded products 
     6,908,000  
     10,256,000  
     13,076,000  
     30,808,000 
  
    Other revenues 
     141,000  
     228,000  
     312,000  
     375,000 
  
    Branded revenue, net 
     51,582,000  
     28,552,000  
     121,636,000  
     69,780,000 
  
    ImprimisRx revenue, net 
     20,056,000  
     20,705,000  
     61,575,000  
     63,003,000 

    Total revenues, net 
    $71,638,000  
    $49,257,000  
    $183,211,000  
    $132,783,000 

Other
than IHEEZO and VEVYE, no other products accounted for more than 10% of total revenues for the periods presented.

Customer
and Supplier Concentrations

Substantially
all of the Company’s Branded sales are made to third-party distributors who sell the products to pharmacies and to the end-users.
There were two customers who